Convenient determination of serum HER‐2 status in breast cancer patients using Raman spectroscopy

Given the significant therapeutic efficacy of anti‐HER‐2 treatment, the HER‐2 status is a crucial piece of information that must be obtained in breast cancer patients. Currently, as per guidelines, HER‐2 status is typically acquired from breast tissue of patients. However, there is growing interest in obtaining HER‐2 status from serum and other samples due to the convenience and potential for dynamic monitoring. In this study, we have developed a serum Raman spectroscopy technique that allows for the rapid acquisition of HER‐2 status in a convenient manner. The established HER‐2 negative and positive classification model achieved an area under the curve of 0.8334. To further validate the reliability of our method, we replicated the process using immunohistochemistry and in situ hybridization. The results demonstrate that serum Raman spectroscopy, coupled with artificial intelligence algorithms, is an effective technical approach for obtaining HER‐2 status. The HER‐2 status of breast cancer patients can be rapidly and conveniently obtained through serum Raman spectroscopy.